Benazepril - Revision history

Elcatracho: /* Administration */

2021-03-08T15:57:54Z

Administration

← Revisión anterior		Revisión del 15:57 8 mar 2021
Línea 1:		Línea 1:
	==Administration==		==Administration==
	*Type: [[ACE inhibitor]]		*Type: [[ACE inhibitor]]
	*Dosage Forms:		*Dosage Forms: 5mg, 10mg, 20mg, 40mg
	*Routes of Administration: PO		*Routes of Administration: PO
	*Common Trade Names: Lotensin		*Common Trade Names: Lotensin

Elcatracho: /* See Also */

2021-03-08T15:53:34Z

ClaireLewis at 21:30, 19 September 2019

2019-09-19T21:30:18Z

← Revisión anterior		Revisión del 21:30 19 sep 2019
Línea 73:		Línea 73:
	<references/>		<references/>

	[[Category:Pharmacology]]		[[Category:Pharmacology]] [[Category:Cardiology]]

Fletc151: /* References */

2019-06-10T13:19:07Z

References

← Revisión anterior		Revisión del 13:19 10 jun 2019
Línea 60:		Línea 60:

	==References==		==References==
			*ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, “Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),” JAMA, 2002, 288(23):2981-97. [PubMed 12479763]
			*American College of Obstetricians and Gynecologists (ACOG), Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122-1131. [PubMed 24150027 ]
			*American Diabetes Association (ADA). Diabetes Care. 2019;42(suppl 1):S1-S193. http://care.diabetesjournals.org/content/42/Supplement_1. Accessed January 10, 2019.
			*Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol. 2014;64(24):2713-2714]. J Am Coll Cardiol. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017. [PubMed 25260718]
			*Antman EM, Anbe SC, Alpert JS, et al, “ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),” Circulation, 2004, 110(5):588-636. Available at http://www.circulationaha.org/cgi/content/full/110/5/588 [PubMed 15289388]
			*Antman EM, Hand M, Armstrong PW, et al, “2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” J Am Coll Cardiol, 2008, 51(2):210-49. [PubMed 18191746]
			*Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. Philadelphia, PA: American College of Physicians; 2007.
			*Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160(5):685-693. [PubMed 10724055]
			*Balfour JA, Goa KL. Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. Drugs. 1991;42(3):511-539. Review. [PubMed 1720384]
			*Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, "Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada," Can J Diabetes, 2013, 35(Suppl 1):1-212.

	<references/>		<references/>

	[[Category:Pharmacology]]		[[Category:Pharmacology]]

ClaireLewis: Created page with "==Administration== Type: ACE inhibitor Dosage Forms: Routes of Administration: PO Common Trade Names: Lotensin ==Adult Dosing== *2-80mg PO in one or two daily doses..."

2019-01-26T22:51:37Z

Created page with "==Administration== *Type: ACE inhibitor *Dosage Forms: *Routes of Administration: PO *Common Trade Names: Lotensin ==Adult Dosing== *2-80mg PO in one or two daily doses..."

Página nueva

==Administration==
*Type: [[ACE inhibitor]]
*Dosage Forms:
*Routes of Administration: PO
*Common Trade Names: Lotensin

==Adult Dosing==
*2-80mg PO in one or two daily doses

==Pediatric Dosing==
*>6yo: 0.2-0.6mg/kg daily, max 40mg/day

==Special Populations==
===[[Drug pregnancy categories|Pregnancy Rating]]===
*Category D (fetal risk demonstrated)

===Lactation risk===
*Infant risk is minimal

===Renal Dosing===
*Adult: GFR <30 or Cr >3: 5-40mg daily
*Pediatric: not recommended if GFR <30

===Hepatic Dosing===
*Adult: Not established
*Pediatric: Not established

==Contraindications==
*Allergy to class/drug
*Angioedema history
*Concomitant aliskiren use in diabetic patients
*Concomitant or recent (<36h) neprilysin inhibitors (e.g. sacubitril)

==Adverse Reactions==
===Serious===
*[[Angioedema]], anaphylactoid reaction
*[[SJS]]
*[[Agranulocytosis]], [[neutropenia
*Hepatic necrosis, increased LFTs
*Renal impairment

===Common===
*[[Dizziness]], [[Headache]]
*[[Cough]]
*Fatigue

==Pharmacology==
*Half-life: Adult: 10-11h, pediatric: ~5h
*Metabolism: hepatic
*Excretion: renal, biliary

==Mechanism of Action==
*ACE inhibitor: inhibits conversion of angiotensin I to angiotensin II, which decreases vasopressor activity and aldosterone activity

==Comments==

==See Also==
*[[ACE inhibitors]]

==References==
<references/>

[[Category:Pharmacology]]